02133nas a2200253 4500000000100000008004100001260004400042100001600086700001400102700001600116700001500132700001600147700001600163700001700179700001400196700001200210700001900222700001200241245011400253856007300367490000700440520141800447022001401865 2025 d bSpringer Science and Business Media LLC1 aSpaziante M1 aAgresta A1 aD’Amato M1 aDe Carli G1 aTonziello G1 aVantaggio V1 aMalatesta GN1 aGirardi E1 aBarca A1 aScognamiglio P1 aVairo F00aPost-COVID-19 resurgence of scabies’ cases in the Lazio Region, Italy: a new emerging public health threat? uhttps://link.springer.com/content/pdf/10.1186/s40249-025-01279-8.pdf0 v143 a

Abstract

Scabies represents a global health issue and in 2017 was added to the World Health Organization’s list of neglected tropical diseases. In European and Middle Eastern countries, cases are sporadic while recent surveillance data have pointed out an increasing incidence among vulnerable populations. Regional cases for Lazio, Italy, reported from 2017 to 2023 to the national infectious disease surveillance system were analyzed. In Lazio, just after the coronavirus disease 2019 (COVID-19) pandemic onset, a significant and immediate reduction in the incidence of scabies was recorded (− 79.6%) followed by a progressive and relevant increase (143.4% from 2020 to 2021, 142.3% from 2021 to 2022 and 170.3% from 2022 to 2023). Consistently, the number of scabies outbreaks, after a decrease following the first COVID-19 wave, has progressively increased over time, mainly due to the occurrence of outbreaks in long term facilities (750% from 2020 to 2023). The increased incidence may also be driven by the “pseudo-resistance” phenomenon (under dosed/early-discontinued treatment, suboptimal adherence, reduced drug bioavailability), but also by reduced in-vitro susceptibility to the mainly used scabicides. The rapidly evolving epidemiology of scabies in our country, as documented also in other regions, calls for a comprehensive approach to effectively address the problem.

 a2049-9957